Please Wait.....
Report
Vaccine Adjuvants Market By Type (Immunostimulants, Vehicles and Mucosal Adjuvants), By Disease (Infectious Diseases, Others), By Application (Research, Commercial): Global Opportunity Analysis and Industry Forecast, 2023-2032
Market Report I 2024-02-01 I 280 Pages I Allied Market Research
The vaccine adjuvants market was valued at $1 billion in 2022 and is estimated to reach $1.5billion by 2032, exhibiting a CAGR of 4% from 2023 to 2032.Adjuvants are substances that are added to vaccinations in order to strengthen and increase the immune system's reaction to the antigens within the vaccine itself. The components of vaccinations called antigens are what cause the immune system to create antibodies and other immunological responses. Adjuvants assist to increase the efficiency of vaccines by fostering a stronger, longer-lasting, and more robust immune response.
Adjuvants for vaccinations are primarily used to improve an antigen's capacity to elicit an immune response, making it more robust and long-lasting. Adjuvants can accomplish this through a number of strategies, including encouraging immune cell recruitment and activation, boosting immune cell uptake of antigens, and strengthening the immune system's overall identification of the vaccine's components.
Adjuvants enable vaccine manufacturers to employ lower concentrations of antigens, which lowers manufacturing costs and might improve vaccination safety. Furthermore, adjuvants are essential for enhancing the effectiveness of vaccinations, especially when a strong immune response is required, as in the case of elderly patients or those with compromised immune systems.Furthermore, adjuvants for vaccinations are put through extensive testing to make sure they are safe and effective before being added to vaccines. Achieving a balance between boosting the immune response and preserving vaccine safety is the target for the manufacturers and researchers.
The market for vaccine adjuvants is expanding and developing due to a number of causes. The growing need for safer and more effective vaccines is the driving force behind these issues. Vaccine research and development are driven by the increasing prevalence of infectious illnesses and the ongoing efforts to counter new health risks. Adjuvants are becoming more and more necessary to improve the effectiveness of vaccinations as more are being created.
Moreover, global immunization programs are being expanded by various governments globally and also by the international health organizations, which is driving up demand for vaccinations. Adjuvants are critical to the success of large-scale vaccination programs because they enhance the immune response. Also, a rise in the creation of therapeutic vaccines has been attributed to the rising incidence of chronic diseases like cancer. Adjuvants play a crucial role in augmenting the efficacy of these vaccines, hence fueling the vaccine adjuvants market expansion.
Moreover, as the population ages, there is a greater chance of developing several diseases. When creating vaccinations for older persons who could have a compromised immune response, adjuvants become more crucial. A further factor driving up demand for adjuvanted vaccinations is this demographic trend.
Technological developments in adjuvants and understanding of immune system interactions has improved as a result of developments in immunology and biotechnology. This has aided in the creation of adjuvants that are more focused and effective, spurring market innovation. Both public and private sectors are investing significantly in research and development of vaccines and adjuvants. These investments aim to address unmet medical needs and enhance the overall efficacy and safety profile of vaccines, thus boosting the market growth.
Regulatory agencies recognizing the importance of vaccine adjuvants in vaccine development provide guidelines and support for their incorporation which increases the adoption of adjuvants. This encourages manufacturers to invest in the development and commercialization of adjuvanted vaccines, which also drives the growth of the market.
The vaccine adjuvants market is segmented into type, disease, application, and region. On the basis of type, the market is bifurcated into immunostimulants and vehicles andmucosal adjuvants. The immunostimulants segment is further segmented into toll like receptor and others. As per disease, the market is divided into infectious diseases and cancer. The infectious diseases segment market is further segregated into hepatitis and others. On the basis of application, the market is classified into research and commercial.
Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (India, China, Japan, Australia, South Korea, and rest of Asia-Pacific), and Latin America (Brazil, Argentina, Colombia and rest of Latin America) and Middle East and Africa (GCC, South Africa, North Africa, and rest of LAMEA).
The major players that operate in the vaccine adjuvants market include Adjuvatis, Dynavax Technologies Corporation, GSK, Croda International, Novovax, SEPPIC, Agenus Inc, Invivogen, SPI Pharma, and Aurorium. These key players have adopted key strategies such as partnership and business expansion to expand their product portfolio.
Key Benefits for Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vaccine adjuvants market analysis from 2022 to 2032 to identify the prevailing vaccine adjuvants market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the vaccine adjuvants market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global vaccine adjuvants market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Strategic Recommedations
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
Key Market Segments
By Type
- Immunostimulants
- Type
- Toll-like receptor
- Others
- Vehicles and Mucosal Adjuvants
By Disease
- Infectious Diseases
- Type
- Hepatitis
- Others
- Others
By Application
- Research
- Commercial
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Colombia
- Argentina
- Rest of Latin America
- Middle East and Africa
- Gcc
- South Africa
- North Africa
- Rest of Middle East And Africa
- Key Market Players
- Dynavax Technologies Corporation
- Novovax
- Agenus Inc.
- Adjuvatis
- Aurorium
- InvivoGen
- SEPPIC
- GlaxoSmithKline plc
- SPI Pharma, Inc.
- Croda International Plc
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: VACCINE ADJUVANTS MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Immunostimulants
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Immunostimulants Vaccine Adjuvants Market by Type
4.3. Vehicles and Mucosal Adjuvants
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: VACCINE ADJUVANTS MARKET, BY DISEASE
5.1. Overview
5.1.1. Market size and forecast
5.2. Infectious Diseases
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.2.4. Infectious Diseases Vaccine Adjuvants Market by Type
5.3. Others
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: VACCINE ADJUVANTS MARKET, BY APPLICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Research
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Commercial
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: VACCINE ADJUVANTS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Type
7.2.3. Market size and forecast, by Disease
7.2.4. Market size and forecast, by Application
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Type
7.2.5.1.2. Market size and forecast, by Disease
7.2.5.1.3. Market size and forecast, by Application
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Type
7.2.5.2.2. Market size and forecast, by Disease
7.2.5.2.3. Market size and forecast, by Application
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Type
7.2.5.3.2. Market size and forecast, by Disease
7.2.5.3.3. Market size and forecast, by Application
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Type
7.3.3. Market size and forecast, by Disease
7.3.4. Market size and forecast, by Application
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Type
7.3.5.1.2. Market size and forecast, by Disease
7.3.5.1.3. Market size and forecast, by Application
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Type
7.3.5.2.2. Market size and forecast, by Disease
7.3.5.2.3. Market size and forecast, by Application
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Type
7.3.5.3.2. Market size and forecast, by Disease
7.3.5.3.3. Market size and forecast, by Application
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Type
7.3.5.4.2. Market size and forecast, by Disease
7.3.5.4.3. Market size and forecast, by Application
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Type
7.3.5.5.2. Market size and forecast, by Disease
7.3.5.5.3. Market size and forecast, by Application
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Type
7.3.5.6.2. Market size and forecast, by Disease
7.3.5.6.3. Market size and forecast, by Application
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Type
7.4.3. Market size and forecast, by Disease
7.4.4. Market size and forecast, by Application
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Type
7.4.5.1.2. Market size and forecast, by Disease
7.4.5.1.3. Market size and forecast, by Application
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Type
7.4.5.2.2. Market size and forecast, by Disease
7.4.5.2.3. Market size and forecast, by Application
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Type
7.4.5.3.2. Market size and forecast, by Disease
7.4.5.3.3. Market size and forecast, by Application
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Type
7.4.5.4.2. Market size and forecast, by Disease
7.4.5.4.3. Market size and forecast, by Application
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Type
7.4.5.5.2. Market size and forecast, by Disease
7.4.5.5.3. Market size and forecast, by Application
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Type
7.4.5.6.2. Market size and forecast, by Disease
7.4.5.6.3. Market size and forecast, by Application
7.5. Latin America
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Type
7.5.3. Market size and forecast, by Disease
7.5.4. Market size and forecast, by Application
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Type
7.5.5.1.2. Market size and forecast, by Disease
7.5.5.1.3. Market size and forecast, by Application
7.5.5.2. Colombia
7.5.5.2.1. Market size and forecast, by Type
7.5.5.2.2. Market size and forecast, by Disease
7.5.5.2.3. Market size and forecast, by Application
7.5.5.3. Argentina
7.5.5.3.1. Market size and forecast, by Type
7.5.5.3.2. Market size and forecast, by Disease
7.5.5.3.3. Market size and forecast, by Application
7.5.5.4. Rest of Latin America
7.5.5.4.1. Market size and forecast, by Type
7.5.5.4.2. Market size and forecast, by Disease
7.5.5.4.3. Market size and forecast, by Application
7.6. Middle East and Africa
7.6.1. Key market trends, growth factors and opportunities
7.6.2. Market size and forecast, by Type
7.6.3. Market size and forecast, by Disease
7.6.4. Market size and forecast, by Application
7.6.5. Market size and forecast, by country
7.6.5.1. Gcc
7.6.5.1.1. Market size and forecast, by Type
7.6.5.1.2. Market size and forecast, by Disease
7.6.5.1.3. Market size and forecast, by Application
7.6.5.2. South Africa
7.6.5.2.1. Market size and forecast, by Type
7.6.5.2.2. Market size and forecast, by Disease
7.6.5.2.3. Market size and forecast, by Application
7.6.5.3. North Africa
7.6.5.3.1. Market size and forecast, by Type
7.6.5.3.2. Market size and forecast, by Disease
7.6.5.3.3. Market size and forecast, by Application
7.6.5.4. Rest of Middle East And Africa
7.6.5.4.1. Market size and forecast, by Type
7.6.5.4.2. Market size and forecast, by Disease
7.6.5.4.3. Market size and forecast, by Application
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Dynavax Technologies Corporation
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Novovax
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. SEPPIC
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.4. Agenus Inc.
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Aurorium
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.6. Adjuvatis
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.7. InvivoGen
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.8. GlaxoSmithKline plc
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. SPI Pharma, Inc.
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.10. Croda International Plc
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
LIST OF TABLES
TABLE 01. GLOBAL VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 02. VACCINE ADJUVANTS MARKET FOR IMMUNOSTIMULANTS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. GLOBAL IMMUNOSTIMULANTS VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 04. VACCINE ADJUVANTS MARKET FOR VEHICLES AND MUCOSAL ADJUVANTS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 06. VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL INFECTIOUS DISEASES VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 08. VACCINE ADJUVANTS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 10. VACCINE ADJUVANTS MARKET FOR RESEARCH, BY REGION, 2022-2032 ($MILLION)
TABLE 11. VACCINE ADJUVANTS MARKET FOR COMMERCIAL, BY REGION, 2022-2032 ($MILLION)
TABLE 12. VACCINE ADJUVANTS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 17. U.S. VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 18. U.S. VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 19. U.S. VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 20. CANADA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 21. CANADA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 22. CANADA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 23. MEXICO VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 24. MEXICO VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 25. MEXICO VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 26. EUROPE VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 27. EUROPE VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 28. EUROPE VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 29. EUROPE VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 30. GERMANY VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 31. GERMANY VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 32. GERMANY VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 33. FRANCE VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 34. FRANCE VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 35. FRANCE VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 36. UK VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 37. UK VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 38. UK VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 39. ITALY VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 40. ITALY VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 41. ITALY VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 42. SPAIN VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 43. SPAIN VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 44. SPAIN VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 45. REST OF EUROPE VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 48. ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 52. JAPAN VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 53. JAPAN VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 54. JAPAN VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 55. CHINA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 56. CHINA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 57. CHINA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 58. INDIA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 59. INDIA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 60. INDIA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 64. SOUTH KOREA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 70. LATIN AMERICA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 71. LATIN AMERICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 72. LATIN AMERICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 73. LATIN AMERICA VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 74. BRAZIL VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 75. BRAZIL VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 76. BRAZIL VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 77. COLOMBIA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 78. COLOMBIA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 79. COLOMBIA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 80. ARGENTINA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 81. ARGENTINA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 82. ARGENTINA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 83. REST OF LATIN AMERICA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 84. REST OF LATIN AMERICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 85. REST OF LATIN AMERICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 86. MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 87. MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 88. MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 89. MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 90. GCC VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 91. GCC VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 92. GCC VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 93. SOUTH AFRICA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 94. SOUTH AFRICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 95. SOUTH AFRICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 96. NORTH AFRICA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 97. NORTH AFRICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 98. NORTH AFRICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 99. REST OF MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 100. REST OF MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
TABLE 101. REST OF MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 102. DYNAVAX TECHNOLOGIES CORPORATION: KEY EXECUTIVES
TABLE 103. DYNAVAX TECHNOLOGIES CORPORATION: COMPANY SNAPSHOT
TABLE 104. DYNAVAX TECHNOLOGIES CORPORATION: PRODUCT SEGMENTS
TABLE 105. DYNAVAX TECHNOLOGIES CORPORATION: PRODUCT PORTFOLIO
TABLE 106. DYNAVAX TECHNOLOGIES CORPORATION: KEY STRATERGIES
TABLE 107. NOVOVAX: KEY EXECUTIVES
TABLE 108. NOVOVAX: COMPANY SNAPSHOT
TABLE 109. NOVOVAX: PRODUCT SEGMENTS
TABLE 110. NOVOVAX: PRODUCT PORTFOLIO
TABLE 111. SEPPIC: KEY EXECUTIVES
TABLE 112. SEPPIC: COMPANY SNAPSHOT
TABLE 113. AGENUS INC.: KEY EXECUTIVES
TABLE 114. AGENUS INC.: COMPANY SNAPSHOT
TABLE 115. AGENUS INC.: PRODUCT SEGMENTS
TABLE 116. AGENUS INC.: PRODUCT PORTFOLIO
TABLE 117. AGENUS INC.: KEY STRATERGIES
TABLE 118. AURORIUM: KEY EXECUTIVES
TABLE 119. AURORIUM: COMPANY SNAPSHOT
TABLE 120. AURORIUM: PRODUCT SEGMENTS
TABLE 121. AURORIUM: PRODUCT PORTFOLIO
TABLE 122. ADJUVATIS: KEY EXECUTIVES
TABLE 123. ADJUVATIS: COMPANY SNAPSHOT
TABLE 124. ADJUVATIS: PRODUCT SEGMENTS
TABLE 125. ADJUVATIS: SERVICE SEGMENTS
TABLE 126. ADJUVATIS: PRODUCT PORTFOLIO
TABLE 127. INVIVOGEN: KEY EXECUTIVES
TABLE 128. INVIVOGEN: COMPANY SNAPSHOT
TABLE 129. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 130. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 131. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
TABLE 132. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 133. GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 134. SPI PHARMA, INC.: KEY EXECUTIVES
TABLE 135. SPI PHARMA, INC.: COMPANY SNAPSHOT
TABLE 136. CRODA INTERNATIONAL PLC: KEY EXECUTIVES
TABLE 137. CRODA INTERNATIONAL PLC: COMPANY SNAPSHOT
LIST OF FIGURES
FIGURE 01. VACCINE ADJUVANTS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF VACCINE ADJUVANTS MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN VACCINE ADJUVANTS MARKET
FIGURE 04. TOP INVESTMENT POCKETS IN VACCINE ADJUVANTS MARKET (2023-2032)
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. BARGAINING POWER OF BUYERS
FIGURE 07. THREAT OF SUBSTITUTION
FIGURE 08. THREAT OF SUBSTITUTION
FIGURE 09. COMPETITIVE RIVALRY
FIGURE 10. GLOBAL VACCINE ADJUVANTS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. VACCINE ADJUVANTS MARKET, BY TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR IMMUNOSTIMULANTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR VEHICLES AND MUCOSAL ADJUVANTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. VACCINE ADJUVANTS MARKET, BY DISEASE, 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR RESEARCH, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR COMMERCIAL, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. VACCINE ADJUVANTS MARKET BY REGION, 2022 AND 2032(%)
FIGURE 21. U.S. VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 22. CANADA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 23. MEXICO VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 24. GERMANY VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 25. FRANCE VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 26. UK VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 27. ITALY VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 28. SPAIN VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 29. REST OF EUROPE VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 30. JAPAN VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 31. CHINA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 32. INDIA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 33. AUSTRALIA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 34. SOUTH KOREA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 35. REST OF ASIA-PACIFIC VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 36. BRAZIL VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 37. COLOMBIA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 38. ARGENTINA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 39. REST OF LATIN AMERICA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 40. GCC VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 41. SOUTH AFRICA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 42. NORTH AFRICA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 43. REST OF MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 45. COMPETITIVE DASHBOARD
FIGURE 46. COMPETITIVE HEATMAP: VACCINE ADJUVANTS MARKET
FIGURE 47. TOP PLAYER POSITIONING, 2022
FIGURE 48. DYNAVAX TECHNOLOGIES CORPORATION: NET REVENUE, 2019-2022 ($MILLION)
FIGURE 49. DYNAVAX TECHNOLOGIES CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 50. DYNAVAX TECHNOLOGIES CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 51. NOVOVAX: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 52. AGENUS INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 53. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 54. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 55. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security